New Serological Markers for Eosinophilic Esophagitis
|ClinicalTrials.gov Identifier: NCT01624129|
Recruitment Status : Unknown
Verified February 2011 by Technische Universität München.
Recruitment status was: Recruiting
First Posted : June 20, 2012
Last Update Posted : June 20, 2012
|Condition or disease||Intervention/treatment|
|Eosinophilic Esophagitis||Drug: Fluticasone|
The eosinophilic esophagitis (EE) is chronic inflammatory and immunological disease. The diagnosis of EE is based upon large numbers of eosinophils in the esophagus on histopathologic examination (> 20 eosinophils per high powered field in at least one specimen) despite acid suppression with a Proton-Pump-Inhibitor (PPI) for at least two weeks.
There are no diagnostic serological markers for EE so far, so that the purpose of the study is to investigate serological markers which are established in other allergic diseases.
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Study Start Date :||January 2011|
patients with histopathological defined eosinophilic esophagitis
Guideline-based treatment with fluticasone 0,5 ml (1-0-1), step-up or step-down after 3 months based on the histopathological findings
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01624129
|Contact: Monther Bajbouj, MDemail@example.com|
|Contact: Christoph Schlag, MD||+49-89-41402450||Christoph.Schlag@lrz.tum.de|
|II. Medical Department, Technical University Munich||Recruiting|
|Munich, Bavaria, Germany, 81675|
|Contact: Monther Bajbouj, MD 0049-89-41400 firstname.lastname@example.org|
|Principal Investigator:||Monther Bajbouj, MD||Technical University of Munich, 2nd Medical Department|